- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Specially formulated toothpaste developed for desensitizing adults with peanut allergies
Researchers have found in a new study that Oral mucosal immunotherapy (OMIT), delivered as a specially formulated toothpaste is safe and convenient option for desensitizing adults with peanut allergies.
The study was presented at the annual meeting of the American College of Allergy, Asthma & Immunology, held from Nov. 9 to 13 in Anaheim, California.
“OMIT uses a specially formulated toothpaste to deliver allergenic peanut proteins to areas of the oral cavity,” says allergist William Berger, MD, ACAAI member and author of the study. “OMIT as a delivery mechanism for peanut protein has great potential for food allergy desensitization. Due to its targeted delivery and simple administration, it supports the goal of improved adherence.”
This study enrolled 32 adults, age 18-55, with peanut allergy in a 3:1 ratio of active treatment to placebo control. Participants received either an escalating dose of peanut toothpaste or placebo. During this 48-week trial, safety was monitored during the up-dosing and maintenance phases. Exploratory biomarkers were also evaluated, and oral food challenges were conducted. (Exploratory biomarkers are blood tests used to show if a person’s immune system is responding to treatment with an allergen such as peanut.)
“We noted that 100% of those being treated with the toothpaste consistently tolerated the pre-specified protocol highest dose,” says Dr. Berger. “No moderate nor severe systemic reactions occurred in active participants. Non-systemic adverse reactions were mostly local (oral itching), mild, and transient. There was 97% adherence to treatment with no dropouts due to study medication. OMIT appears to be a safe and convenient option for adults with food allergies. The results support continued development of this toothpaste in the pediatric population.”
Additional long-term studies are planned to further evaluate the ongoing use of the toothpaste therapy to provide long-term protection against accidental ingestion of peanut.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751